Clinical validation of the 2021 European Society of Cardiology guidelines on preexisting right bundle branch block in patients undergoing transcatheter aortic valve implantation
Marc Salis MD , Patrick Badertscher MD , Andrea Papa MD , Sven Knecht DSc , Teodor Serban MD , Thomas Nestelberger MD , Christoph Kaiser MD , Gregor Leibundgut MD , Beat Schaer MD , Philipp Krisai MD , Felix Mahfoud MD , Michael Kühne MD , Christian Sticherling MD
{"title":"Clinical validation of the 2021 European Society of Cardiology guidelines on preexisting right bundle branch block in patients undergoing transcatheter aortic valve implantation","authors":"Marc Salis MD , Patrick Badertscher MD , Andrea Papa MD , Sven Knecht DSc , Teodor Serban MD , Thomas Nestelberger MD , Christoph Kaiser MD , Gregor Leibundgut MD , Beat Schaer MD , Philipp Krisai MD , Felix Mahfoud MD , Michael Kühne MD , Christian Sticherling MD","doi":"10.1016/j.hrthm.2024.11.030","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Risk stratification of patients with right bundle branch block (RBBB) undergoing transcatheter aortic valve implantation (TAVI) remains challenging.</div></div><div><h3>Objective</h3><div>This study aimed to evaluate the European Society of Cardiology (ESC) criteria for risk stratification of RBBB patients undergoing TAVI.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed prospectively enrolled patients with preexisting RBBB undergoing TAVI between 2011 and 2023. A surface 12-lead electrocardiogram was available before and after the procedure in all patients. The following ESC criteria were validated: ΔPR interval ≥20 ms, QRS axis change, and transient high-degree atrioventricular block (HAVB) <24 hours after TAVI.</div></div><div><h3>Results</h3><div>Preexisting RBBB was documented in 107 of 1410 patients (7.6%) undergoing TAVI. Mean age was 83 ± 5 years, 34% were female, and 66% received self-expandable valves. Of those 107 patients with preexisting RBBB, 36 (34%) had persistent HAVB lasting longer than 24 hours and received permanent pacemaker therapy. Of the remaining 71 patients, 16 patients (23%) had delayed HAVB during 30 days of follow-up. The ESC criteria identified 81% of patients (13/16) with delayed HAVB during 30-day follow-up while missing 3 patients (19%; 2.8% of the overall cohort). This resulted in a sensitivity of 81% and a negative predictive value of 92%. Meeting the ESC criteria bore a 6-fold increase in the odds for development of HAVB during 30-day follow-up (odds ratio, 6.5; 95% confidence interval, 1.84–30.8; <em>P</em> = .007).</div></div><div><h3>Conclusion</h3><div>In this large cohort of patients with preexisting RBBB undergoing TAVI with contemporary prosthesis and implantation techniques, the ESC criteria—PR prolongation, QRS axis change, and transient HAVB—correctly identified 4 of 5 patients in whom HAVB developed during 30-day follow-up.</div></div>","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":"22 10","pages":"Pages 2625-2634"},"PeriodicalIF":5.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart rhythm","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1547527124036130","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Risk stratification of patients with right bundle branch block (RBBB) undergoing transcatheter aortic valve implantation (TAVI) remains challenging.
Objective
This study aimed to evaluate the European Society of Cardiology (ESC) criteria for risk stratification of RBBB patients undergoing TAVI.
Methods
We retrospectively analyzed prospectively enrolled patients with preexisting RBBB undergoing TAVI between 2011 and 2023. A surface 12-lead electrocardiogram was available before and after the procedure in all patients. The following ESC criteria were validated: ΔPR interval ≥20 ms, QRS axis change, and transient high-degree atrioventricular block (HAVB) <24 hours after TAVI.
Results
Preexisting RBBB was documented in 107 of 1410 patients (7.6%) undergoing TAVI. Mean age was 83 ± 5 years, 34% were female, and 66% received self-expandable valves. Of those 107 patients with preexisting RBBB, 36 (34%) had persistent HAVB lasting longer than 24 hours and received permanent pacemaker therapy. Of the remaining 71 patients, 16 patients (23%) had delayed HAVB during 30 days of follow-up. The ESC criteria identified 81% of patients (13/16) with delayed HAVB during 30-day follow-up while missing 3 patients (19%; 2.8% of the overall cohort). This resulted in a sensitivity of 81% and a negative predictive value of 92%. Meeting the ESC criteria bore a 6-fold increase in the odds for development of HAVB during 30-day follow-up (odds ratio, 6.5; 95% confidence interval, 1.84–30.8; P = .007).
Conclusion
In this large cohort of patients with preexisting RBBB undergoing TAVI with contemporary prosthesis and implantation techniques, the ESC criteria—PR prolongation, QRS axis change, and transient HAVB—correctly identified 4 of 5 patients in whom HAVB developed during 30-day follow-up.
期刊介绍:
HeartRhythm, the official Journal of the Heart Rhythm Society and the Cardiac Electrophysiology Society, is a unique journal for fundamental discovery and clinical applicability.
HeartRhythm integrates the entire cardiac electrophysiology (EP) community from basic and clinical academic researchers, private practitioners, engineers, allied professionals, industry, and trainees, all of whom are vital and interdependent members of our EP community.
The Heart Rhythm Society is the international leader in science, education, and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education, and optimal health care policies and standards.